Filtered By:
Specialty: Drugs & Pharmacology
Therapy: Chemotherapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 77 results found since Jan 2013.

Short interfering RNA in colorectal cancer: is it wise to shoot the messenger?
This study focuses on many innovative siRNA therapies and methodologies for delivering siRNA therapeutics to the malignant site safely and effectively for the treatment of CRC. Treatment of CRC using siRNA-associated nanoparticles (NPs) may inhibit the activity of oncogenes and MDR-related genes by targeting a range of signaling mechanisms. This study summarizes several siRNAs targeting signaling molecules, as well as the therapeutic approaches that might be employed to treat CRC in the future.PMID:37011722 | DOI:10.1016/j.ejphar.2023.175699
Source: European Journal of Pharmacology - April 3, 2023 Category: Drugs & Pharmacology Authors: Kiruthiga Chandramohan Devasahayam Jaya Balan Kasi Pandima Devi Seyed Fazel Nabavi Sara Reshadat Maryam Khayatkashani Sepideh Mahmoodifar Rosanna Filosa Nilofar Amirkhalili Soroush Pishvaei Omolbanin Sargazi Aval Seyed Mohammad Nabavi Source Type: research

Study on co-delivery of pemetrexed disodium and Bcl-2 siRNA by poly- γ-glutamic acid-modified cationic liposomes for the inhibition of NSCLC
Drug Dev Ind Pharm. 2023 Feb 20:1-18. doi: 10.1080/03639045.2023.2182125. Online ahead of print.ABSTRACTDue to the complexity of pathophysiology of non-small cell lung cancer (NSCLC) and susceptibility of single chemotherapy to drug resistance, the combination of drugs and small interfering RNA (siRNA) may produce desired therapeutic effect on NSCLC through action of multiple pathways. We designed to develop poly-γ-glutamic acid-modified cationic liposomes (γ-PGA-CL) to co-deliver pemetrexed disodium (PMX) and siRNA to treat NSCLC. Firstly, γ-PGA was modified on surface of PMX and siRNA co-loaded cationic liposomes by e...
Source: Drug Development and Industrial Pharmacy - February 21, 2023 Category: Drugs & Pharmacology Authors: Huang Xiaoyu Song Ruonan Wang Xiao Kongfang He Rumeng Shan Xie Fei Guihua Huang Source Type: research

SOX2 function in cancers: Association with growth, invasion, stemness and therapy response
Biomed Pharmacother. 2022 Oct 19;156:113860. doi: 10.1016/j.biopha.2022.113860. Online ahead of print.ABSTRACTCancer is a leading cause of death worldwide and around 10 million deaths in 2020 were related to cancer. There are a number of therapeutic modalities for cancer such as chemotherapy, radiotherapy and surgery. However, tumor cells have capacity of developing resistance to chemotherapy and radiotherapy. Genetic mutations participate in development and progression of cancer. The current review focuses on the role of SOX2 transcription factor in cancer. SOX2 has capacity of increasing growth and metastasis of cancer c...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 22, 2022 Category: Drugs & Pharmacology Authors: Sepideh Mirzaei Mahshid Deldar Abad Paskeh Maliheh Entezari Seyed Reza Mirmazloomi Aria Hassanpoor Maryam Aboutalebi Shamin Rezaei Elahe Sadat Hejazi Amirabbas Kakavand Hajar Heidari Shokooh Salimimoghadam Afshin Taheriazam Mehrdad Hashemi Saeed Samarghan Source Type: research

Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer
In this study, we investigated the relation of TLR4 and downstream pathways with immune-check point VISTA in pancreatic cancer proliferation. We initially collected pancreatic cancer-related datasets using the GEPIA2 and UALCAN databases. Based on this data obtained the effect of various concentrations and incubation times of naloxone were used on PANC-1 cells proliferation. A combination of naloxone and VISTA-siRNA were applied, and the effect of both naloxone and combinedtreatment on TLR4, Interleukin 1 receptor associated kinase 4 (IRAK4) and VISTA gene expression were analyzed in pancreatic cancer cells. As a result of...
Source: Investigational New Drugs - February 3, 2022 Category: Drugs & Pharmacology Source Type: research

EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects
Biomed Pharmacother. 2021 Dec 11;146:112532. doi: 10.1016/j.biopha.2021.112532. Online ahead of print.ABSTRACTBrain tumors are responsible for high mortality and morbidity worldwide. The brain tumor treatment depends on identification of molecular pathways involved in progression and malignancy. Enhancer of zeste homolog 2 (EZH2) has obtained much attention in recent years in field of cancer therapy due to its aberrant expression and capacity in modulating expression of genes by binding to their promoter and affecting methylation status. The present review focuses on EZH2 signaling in brain tumors including glioma, gliobla...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - December 15, 2021 Category: Drugs & Pharmacology Authors: Mahshid Deldar Abad Paskeh Atefeh Mehrabi Mohammad Hossein Gholami Amirhossein Zabolian Ehsan Ranjbar Hossein Saleki Adnan Ranjbar Mehrdad Hashemi Yavuz Nuri Ertas Kiavash Hushmandi Sepideh Mirzaei Milad Ashrafizadeh Ali Zarrabi Saeed Samarghandian Source Type: research

The involvement of epithelial-to-mesenchymal transition in doxorubicin resistance: Possible molecular targets
Eur J Pharmacol. 2021 Jul 13:174344. doi: 10.1016/j.ejphar.2021.174344. Online ahead of print.ABSTRACTConsidering the fact that cancer cells can switch among various molecular pathways and mechanisms to ensure their progression, chemotherapy is no longer effective enough in cancer therapy. As an anti-tumor agent, doxorubicin (DOX) is derived from Streptomyces peucetius and can induce cytotoxicity by binding to topoisomerase enzymes to suppress DNA replication, leading to apoptosis and cell cycle arrest. However, efficacy of DOX in suppressing cancer progression is restricted by development of drug resistance. Cancer cells ...
Source: European Journal of Pharmacology - July 16, 2021 Category: Drugs & Pharmacology Authors: Sepideh Mirzaei Asal Jalal Abadi Mohammad Hossein Gholami Farid Hashemi Amirhossein Zabolian Kiavash Hushmandi Ali Zarrabi Maliheh Entezari Amir Reza Aref Haroon Khan Milad Ashrafizadeh Saeed Samarghandian Source Type: research

Metformin-conjugated micellar system with intratumoral pH responsive de-shielding for co-delivery of doxorubicin and nucleic acid.
Abstract A novel PMet-P(cdmPEG2K) polymeric micellar carrier was developed for tumor-targeted co-delivery of DOX and nucleic acids (NA), based on polymetformin and a structure designed to lose the PEG shell in response to the acidic extracellular tumor environment. NA/DOX co-loaded micelleplexes exhibited enhanced inhibition of cell proliferation compared to DOX-loaded micelles, and displayed a higher level of cytotoxicity at an acidic pH (6.8) which mimicks the tumor microenvironment. The PMet-P(cdmPEG2K) micelles achieved significantly improved transfection with either a reporter plasmid or Cy3-siRNA, and enhanc...
Source: Biochemical Pharmacology - February 2, 2021 Category: Drugs & Pharmacology Authors: Liu Y, Sun J, Huang Y, Chen Y, Li J, Liang L, Xu J, Wan Z, Zhang B, Li Z, Li S Tags: Biochem Pharmacol Source Type: research

CPEB4-Promoted Paclitaxel Resistance in Ovarian Cancer In Vitro Relies on Translational Regulation of CSAG2
Conclusion: This study suggests that the drug-resistant protein CSAG2 is translationally induced by CPEB4, which underlies CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro. Thus, interfering CPEB4/CSAG2 axis might be of benefit to overcome paclitaxel-resistant ovarian cancer.
Source: Frontiers in Pharmacology - January 13, 2021 Category: Drugs & Pharmacology Source Type: research